Hold on a minute, says AstraZeneca CEO Pascal Soriot. Now that the dust has settled on Pfizer's failed bid for the U.K. company, Soriot disputes the wisdom of tying his pay–and that of his fellow executives–to the would-be return on that defunct deal.
written on 02.06.2014
AstraZeneca chief bristles at tying exec pay to Pfizer's spurned £55-per-share bid
